- Koninklijke Philips N.V. PHG reported a third-quarter FY22 comparable sales decline of 5% year-on-year to €4.3 billion.
- Continued supply shortages, inflationary pressures, the COVID situation in China, and the Russia-Ukraine war led to the decline.
- The comparable order intake decreased by 6%.
- Also Read: Philips Names Company Insider Roy Jakobs As New CEO, Succeeding Frans van Houten
- Comparable sales for Diagnosis & Treatment businesses declined by 2%.
- The comparable sales in the Connected Care businesses declined 15% Y/Y due to supply challenges.
- The Personal Health businesses recorded a comparable sales growth of 4% Y/Y from the momentum in North America and Western Europe.
- Philips Respironics has produced 4 million replacement devices and repair kits to date.
- Due to lower sales and supply chain headwinds, the adjusted EBITA margin contracted 750 bps to 4.8%.
- Philips used €180 million in operating cash flow.
- Outlook: The supply challenges, macroeconomic environment, and COVID measures in China led to Philips expecting a mid-single-digit comparable sales decline for Q4, with a high-single-to-double-digit Adjusted EBITA margin range.
- During Q2, PHG disclosed a full-year 2022 outlook of 1%-3% comparable sales growth and ~10% Adjusted EBITA margin, driven by 6%-9% comparable sales growth in the second half of 2022.
- For the 2023-2025 period, Philips expected 4%-6% average annual comparable sales growth and an Adjusted EBITA margin of 14%-15%.
- Philips shared plans to reduce its global workforce by around 4,000 roles immediately.
- Price Action: PHG shares closed lower by 1.51% at $13.07 on Friday.
- Photo Via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
